Given its robust modulation of several cellular pathways that are highly relevant to prostate cancer such as AR signaling and the cyclin D1/CDK4/RB axis [40], we tested whether SMIP004 exhibited anti-prostate cancer activity in murine xenograft models. This evidence concerns the gene AR and prostate cancer.